The Role Of PI 3-kinase P110beta In Regulating Thrombus Porosity
Funder
National Health and Medical Research Council
Funding Amount
$518,394.00
Summary
Blood clots blocking blood flow to the brain (stroke) are a major cause of death and disability. Safety concerns limit the use of current therapies to a small subset of patients, and there is an urgent need to identify safer, more effective drugs. Our studies show that inhibitors of the enzyme PI3Kbeta increase the breakdown of blood clots, without increasing bleeding risk. Our preliminary results raise the possibility that PI3Kbeta inhibitors may represent a safe and effective new approach for ....Blood clots blocking blood flow to the brain (stroke) are a major cause of death and disability. Safety concerns limit the use of current therapies to a small subset of patients, and there is an urgent need to identify safer, more effective drugs. Our studies show that inhibitors of the enzyme PI3Kbeta increase the breakdown of blood clots, without increasing bleeding risk. Our preliminary results raise the possibility that PI3Kbeta inhibitors may represent a safe and effective new approach for the treatment of stroke.Read moreRead less
Helping Stroke Physicians Choose Who To Thrombolyse - The Targeting Optimal Thrombolysis Outcomes (TOTO) Study
Funder
National Health and Medical Research Council
Funding Amount
$1,073,140.00
Summary
Thrombolysis using alteplase is one of the most effective treatments for stroke but is currently used in only 5% of stroke cases. A major barrier is a lack of tools to identify who will benefit from treatment, or who might have a major adverse event. In this study we will develop a clinical decision rule based on clinical data, advanced CT imaging, and blood biomarkers to help identify those who will benefit and those likely to bleed, to encourage wider use of this treatment in acute stroke.
Restoring Microcirculatory Perfusion In ST-elevation Myocardial Infarction: The RESTORE MI Study
Funder
National Health and Medical Research Council
Funding Amount
$3,274,537.00
Summary
Current heart attack treatments have focussed on re-opening the blocked coronary artery but despite this, many patients still suffer significant heart damage because of inadequate blood flow to the heart muscle due to damage to the small blood vessels - the microcirculation. This study seeks to identify heart attack patients with damage to the microcirculation and will conduct a randomised trial of clot busting medications to reduce microcirculation damage and to improve heart function.
Intravascular Leukocyte Trafficking During Thromboinflammation
Funder
National Health and Medical Research Council
Funding Amount
$668,742.00
Summary
Unblocking blood vessels to treat heart attack and stroke can unfortunately cause a paradoxical worsening of organ damage, due to increased inflammation upon blood flow restoration. We have identified a novel way in which this side-effect is regulated by the small blood clotting cells platelets, and the protein fibrin. We will investigate ways to reduce the pro-inflammatory role for platelets, and define safer clot busting treatments.
New Approaches To Improve Thrombolysis In Ischaemic Stroke
Funder
National Health and Medical Research Council
Funding Amount
$586,076.00
Summary
Ischaemic stroke is caused by the presence of a blood clot in the brain. The removal of these clots is achieved using an enzyme called tissue-type plasminogen activator (t-PA). While this agent is effective if given to patients within 4.5h of stroke onset, delayed administration can cause cerebral bleeding. This project is to understand how t-PA promotes these unwanted effects in the brain and to devise novel approaches to extend the time window of t-PA administration in these patients.
Degradable Nanocapsules For Thromboprophylaxis And Treatment Of Acute Thrombosis
Funder
National Health and Medical Research Council
Funding Amount
$1,158,447.00
Summary
The consequences of fat build up in vessels such as heart attacks and brain infarcts are the major cause of death in Australia. Clot busters have been proven to be beneficial for patients with heart attacks, clots in the legs or lungs and brain infarcts. However, the currently available drugs have major limitations in efficacy and in safety. The aim of this project is to develop novel drugs that have the potential to improve both significantly.
Tenecteplase Versus Alteplase For Stroke Thrombolysis Evaluation (TASTE) Trial
Funder
National Health and Medical Research Council
Funding Amount
$4,180,030.00
Summary
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) is an Australian-led international randomised trial designed to generate practice-changing evidence by translating the advanced imaging treatment selection approach used in our previous pilot studies. TASTE aims to confirm the superiority of the new-generation clot-dissolving agent, tenecteplase, over the standard agent, alteplase, in the broad group of stroke patients eligible for acute clot-dissolving treatment.
Enhanced Control Of Hypertension And Thrombolysis In Stroke Study (STAY ENCHANTED)
Funder
National Health and Medical Research Council
Funding Amount
$2,437,384.00
Summary
"Clot busting" treatment is the only approved medical treatment for the commonest type of stroke, ischaemic stroke. However, uptake of treatment remains poor, mainly due to the known major risk of bleeding in the brain. STAY ENCHANTED is an international clinical trial to investigate whether "clot-busting" can be made safer using a lower dose and/or immediate blood pressure lowering. A safer more effective regime could have a major global health impact.
Enhanced Control Of Hypertension And Thrombolysis Stroke Study (ENCHANTED)
Funder
National Health and Medical Research Council
Funding Amount
$4,408,568.00
Summary
This is an international multi-centre randomised controlled trial that is evaluating two approaches to improve the benefits, safety and costs associated with the treatment with the clot-busting drug in patients with acute stroke due to blocked blood vessel. The study aims to determine whether a slightly lower dose of the clot busting drug and more intensive control of elevated blood pressure will improve the chances of a patient recovering from this serious illness.
Antibody Targeted Thrombin-activatable ?-plasminogen Fusion Proteins And Nanocapsules For The Treatment Of Acute Thrombosis
Funder
National Health and Medical Research Council
Funding Amount
$536,951.00
Summary
The clinical consequences of atherosclerosis such as myocardial infarction and stroke are the major cause of mortality and morbidity in Australia. Clot dissolving agents have been proven to be beneficial in patients with acute myocardial infarction, vein thrombosis, pulmonary embolism, and stroke. However, the currently available drugs have major limitations in efficacy and in safety. The aim of this project is to develop novel drugs that have the potential to improve both significantly.